These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
322 related articles for article (PubMed ID: 31735488)
1. An Evaluation of the Clinical and Economic Burden Among Older Adult Medicare-Covered Beneficiaries With Treatment-Resistant Depression. Benson C; Szukis H; Sheehan JJ; Alphs L; Yuce H Am J Geriatr Psychiatry; 2020 Mar; 28(3):350-362. PubMed ID: 31735488 [TBL] [Abstract][Full Text] [Related]
2. Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis. Pilon D; Joshi K; Sheehan JJ; Zichlin ML; Zuckerman P; Lefebvre P; Greenberg PE PLoS One; 2019; 14(10):e0223255. PubMed ID: 31600244 [TBL] [Abstract][Full Text] [Related]
3. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions. Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362 [TBL] [Abstract][Full Text] [Related]
4. Descriptive analysis of the economic burden of treatment resistance in a major depressive episode. Cai Q; Sheehan JJ; Wu B; Alphs L; Connolly N; Benson C Curr Med Res Opin; 2020 Feb; 36(2):329-335. PubMed ID: 31540559 [No Abstract] [Full Text] [Related]
5. Economic burden of treatment-resistant depression among veterans in the United States. Szukis H; Joshi K; Huang A; Amos TB; Wang L; Benson CJ Curr Med Res Opin; 2021 Aug; 37(8):1393-1401. PubMed ID: 33879005 [TBL] [Abstract][Full Text] [Related]
6. Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder. Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C Curr Med Res Opin; 2021 Jan; 37(1):123-133. PubMed ID: 33124940 [TBL] [Abstract][Full Text] [Related]
7. Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database. Amos TB; Tandon N; Lefebvre P; Pilon D; Kamstra RL; Pivneva I; Greenberg PE J Clin Psychiatry; 2018; 79(2):. PubMed ID: 29474009 [TBL] [Abstract][Full Text] [Related]
8. Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression? Pilon D; Sheehan JJ; Szukis H; Morrison L; Zhdanava M; Lefebvre P; Joshi K J Affect Disord; 2019 Aug; 255():50-59. PubMed ID: 31128505 [TBL] [Abstract][Full Text] [Related]
9. Association of Treatment-Resistant Depression With Patient Outcomes and Health Care Resource Utilization in a Population-Wide Study. Lundberg J; Cars T; Lööv SÅ; Söderling J; Sundström J; Tiihonen J; Leval A; Gannedahl A; Björkholm C; Själin M; Hellner C JAMA Psychiatry; 2023 Feb; 80(2):167-175. PubMed ID: 36515938 [TBL] [Abstract][Full Text] [Related]
10. Prospective Service Use and Health Care Costs of Medicaid Beneficiaries with Treatment-Resistant Depression. Olfson M; Amos TB; Benson C; McRae J; Marcus SC J Manag Care Spec Pharm; 2018 Mar; 24(3):226-236. PubMed ID: 29485948 [TBL] [Abstract][Full Text] [Related]
11. A retrospective analysis to estimate the healthcare resource utilization and cost associated with treatment-resistant depression in commercially insured US patients. Li G; Zhang L; DiBernardo A; Wang G; Sheehan JJ; Lee K; Reutfors J; Zhang Q PLoS One; 2020; 15(9):e0238843. PubMed ID: 32915863 [TBL] [Abstract][Full Text] [Related]
12. Medicaid spending burden among beneficiaries with treatment-resistant depression. Pilon D; Sheehan JJ; Szukis H; Singer D; Jacques P; Lejeune D; Lefebvre P; Greenberg PE J Comp Eff Res; 2019 Apr; 8(6):381-392. PubMed ID: 30734581 [TBL] [Abstract][Full Text] [Related]
13. Economic Burden of Treatment-Resistant Depression on the U.S. Health Care System. Sussman M; O'sullivan AK; Shah A; Olfson M; Menzin J J Manag Care Spec Pharm; 2019 Jul; 25(7):823-835. PubMed ID: 31232205 [TBL] [Abstract][Full Text] [Related]
14. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States. Zhdanava M; Pilon D; Ghelerter I; Chow W; Joshi K; Lefebvre P; Sheehan JJ J Clin Psychiatry; 2021 Mar; 82(2):. PubMed ID: 33989464 [TBL] [Abstract][Full Text] [Related]
15. Understanding the Relationship Between Depression Symptom Severity and Health Care Costs for Patients With Treatment-Resistant Depression. Lynch FL; Dickerson JF; O'Keeffe-Rosetti M; Chow W; Pesa J J Clin Psychiatry; 2022 Feb; 83(2):. PubMed ID: 35120286 [No Abstract] [Full Text] [Related]
16. A retrospective chart review study to quantify the monthly medical resource use and costs of treating patients with treatment resistant depression in the United Kingdom. Denee T; Ming T; Waller J; Bailey T; Rajkovic-Hooley O; Middleton-Dalby C; Le HH; Zhang Q; McCrone P; Taylor D Curr Med Res Opin; 2021 Feb; 37(2):311-319. PubMed ID: 33253055 [TBL] [Abstract][Full Text] [Related]
18. Use of home health and other healthcare delivery pathways among privately insured patients with and without treatment-resistant depression. Pilon D; Szukis H; Singer D; Morrison L; Sheehan JJ; Lefebvre P Curr Med Res Opin; 2020 May; 36(5):865-874. PubMed ID: 31985319 [No Abstract] [Full Text] [Related]
19. Economic impact of treatment-resistant depression: A retrospective observational study. Pérez-Sola V; Roca M; Alonso J; Gabilondo A; Hernando T; Sicras-Mainar A; Sicras-Navarro A; Herrera B; Vieta E J Affect Disord; 2021 Dec; 295():578-586. PubMed ID: 34509073 [TBL] [Abstract][Full Text] [Related]
20. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder. Ta JT; Sullivan SD; Tung A; Oliveri D; Gillard P; Devine B J Manag Care Spec Pharm; 2021 Feb; 27(2):223-239. PubMed ID: 33506730 [No Abstract] [Full Text] [Related] [Next] [New Search]